Ticker > Company >

Ishita Drugs & Inds. share price

Ishita Drugs & Industries Ltd.

BSE: 524400 SECTOR: Pharmaceuticals & Drugs  10k   44   3

71.80
-3.89 (-5.14%)
BSE: Today, 04:00 PM

Price Summary

Today's High

₹ 75.85

Today's Low

₹ 71.8

52 Week High

₹ 104.75

52 Week Low

₹ 56

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

21.47 Cr.

Enterprise Value

16.66 Cr.

No. of Shares

0.3 Cr.

P/E

28.97

P/B

2.09

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  34.33

CASH

4.81 Cr.

DEBT

0 Cr.

Promoter Holding

49.8 %

EPS (TTM)

₹  2.48

Sales Growth

25.81%

ROE

7.84 %

ROCE

10.74%

Profit Growth

29.63 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year25.81%
3 Year2.88%
5 Year10.82%

Profit Growth

1 Year29.63%
3 Year-3.37%
5 Year16.32%

ROE%

1 Year7.84%
3 Year8.05%
5 Year8.72%

ROCE %

1 Year10.74%
3 Year10.88%
5 Year11.56%

Debt/Equity

0

Price to Cash Flow

10.12

Interest Cover Ratio

11.9989

CFO/PAT (5 Yr. Avg.)

0.761871223801924

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 49.80 0.00
Jun 2024 49.80 0.00
Mar 2024 49.42 0.00
Dec 2023 49.38 0.00
Sep 2023 49.38 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has significantly decreased its debt by 0.9604251 Cr.
  • Company is virtually debt free.
  • Company’s PEG ratio is 0.977767948168559.
  • The company has an efficient Cash Conversion Cycle of 40.6543 days.
  • Company has a healthy liquidity position with current ratio of 11.1352.

 Limitations

  • The company has shown a poor profit growth of -3.37178904698935% for the Past 3 years.
  • The company has shown a poor revenue growth of 2.87624920066223% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 4.4 3.21 4.5 3.03 3.27
Total Expenditure 4.18 2.98 4.2 2.85 3.04
Operating Profit 0.22 0.23 0.29 0.17 0.24
Other Income 0.1 0.01 0.1 0.06 0.05
Interest 0.01 0.04 0.02 0.01 0
Depreciation 0.03 0.03 0.01 0.03 0.03
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.28 0.16 0.37 0.2 0.26
Tax 0.07 0.04 0.09 0.05 0.06
Profit After Tax 0.21 0.12 0.28 0.15 0.2
Adjusted EPS (Rs) 0.7 0.39 0.94 0.49 0.65

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 14.83 13.95 14.09 12.07 15.19
Total Expenditure 14.07 13.03 13 11.31 14.28
Operating Profit 0.76 0.92 1.09 0.76 0.91
Other Income 0.16 0.31 0.11 0.2 0.28
Interest 0.03 0.03 0.02 0.05 0.09
Depreciation 0.18 0.15 0.13 0.13 0.11
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.71 1.05 1.04 0.78 0.99
Tax 0.17 0.22 0.24 0.2 0.24
Net Profit 0.55 0.83 0.8 0.58 0.75
Adjusted EPS (Rs.) 1.83 2.77 2.69 1.93 2.5

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 2.99 2.99 2.99 2.99 2.99
Total Reserves 3.97 4.8 5.61 6.18 6.93
Borrowings 0.04 0 0 0 0
Other N/C liabilities 0.05 0.04 0.03 0.02 0.02
Current liabilities 2.5 1.43 2.63 2.21 0.87
Total Liabilities 9.55 9.26 11.25 11.41 10.81
Assets
Net Block 1.14 1 0.88 0.89 0.8
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.21 0.23 0.27 0.27 0.27
Loans & Advances 0.05 0.05 0.05 0.07 0.08
Other N/C Assets 0 0 0 0 0
Current Assets 8.15 7.99 10.05 10.18 9.66
Total Assets 9.55 9.26 11.25 11.41 10.81
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 0.71 1.05 1.04 0.78 0.99
Adjustment 0.05 -0.14 0.05 -0.02 -0.08
Changes in Assets & Liabilities 0.46 -1.36 2.24 -3.45 1.45
Tax Paid -0.18 -0.23 -0.25 -0.21 -0.24
Operating Cash Flow 1.05 -0.67 3.08 -2.9 2.12
Investing Cash Flow -1.15 2.45 -0.93 0.59 0.13
Financing Cash Flow 0.09 -0.24 0 1.05 -0.87
Net Cash Flow -0.01 1.54 2.14 -1.25 1.38

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 49.38 49.38 49.42 49.80 49.80
abha agrawal 7.95 7.95 7.99 8.37 8.37
agrawal jagdishprasad g 2.84 2.84 2.84 2.84 2.84
divya sumit agrawal 3.48 3.48 3.48 3.48 3.48
ishita agrawal 0.84 0.84 0.84 0.84 0.84
ishita overseas private l... 4.35 4.35 4.35 4.35 4.35
krishn sumit agrawal 3.01 3.01 3.01 3.01 3.01
shri jagdish agrawal 5.86 5.86 5.86 5.86 5.86
sumit agrawal 9.77 9.77 9.77 9.77 9.77
umang financial services ... 9.94 9.94 9.94 9.94 9.94
varlika sumit agrawal 1.34 1.34 1.34 1.34 1.34
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 50.62 50.62 50.58 50.20 50.20
mahendra girdharilal wadh... - - - 1.00 1.37
patel bhupesh vahalabhai 4.18 3.34 3.43 3.43 1.84
sangeetha s 1.67 1.65 1.27 1.27 1.27
vikkramm chandirramani - - - - 1.35

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Ishita Drugs & Inds. Stock Price Analysis and Quick Research Report. Is Ishita Drugs & Inds. an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ishita Drugs & Inds. and its performance over the period of time. Ishita Drugs & Inds. stock price today is Rs 71.8.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Ishita Drugs & Inds. cash from the operating activity was Rs 2.1207548 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ishita Drugs & Inds. has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ishita Drugs & Inds. , the EPS growth was 29.6338 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ishita Drugs & Inds. has OPM of 5.98159976063097 % which is a bad sign for profitability.
     
  • ROE: Ishita Drugs & Inds. have a poor ROE of 7.8399 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Ishita Drugs & Inds. is Rs 71.8. One can use valuation calculators of ticker to know if Ishita Drugs & Inds. share price is undervalued or overvalued.
Last Updated on:
Brief about Ishita Drugs & Inds.
X